Condition: Pericarditis · Sponsor: ASST Fatebenefratelli Sacco
This study aims to investigate the pathophysiology of recurrent pericarditis (RP) by testing for neutralizing autoantibodies against interleukin-1 receptor antagonist (IL-1RA) and measuring soluble urokinase plasminogen activator receptor (suPAR) levels. The hypothesis is that these tests will provide insights into both the inflammatory and non-inflammatory phenotypes of RP, shedding light on the underlying mechanisms. The study will assess the correlation between antibody levels, suPAR levels, and markers of cardiac damage and inflammation. Longitudinal testing during acute episodes and intercritical phases is also planned. The results may guide the use of anakinra, an IL-1 receptor antagonist, in specific clinical scenarios and optimize treatment strategies for RP.
This description comes directly from the study's public registry record.
Maddalena A Wu · +393392883379 · maddalena.wu@unimi.it
Always discuss trial participation with your own doctor first.
| Saarland University | Homburg, Germany | Recruiting |
| University Children's Hospital Muenster | Münster, Germany | Not Yet Recruiting |
| University Hospital Tübingen | Tübingen, Germany | Not Yet Recruiting |
| A.O.U. Careggi | Florence, Italy | Not Yet Recruiting |
| Luigi Sacco Hospital - ASST Fatebenefratelli Sacco | Milan, Italy | Recruiting |
| Fatebenefratelli Hospital - ASST Fatebenefratelli Sacco | Milan, Italy | Recruiting |
| Ospedale Galeazzi Sant'Ambrogio - IRCCS, Poliambulatorio Cardiovascolare Cardiologia Universitaria | Milan, Italy | Not Yet Recruiting |
| Policlinico di Milano Ospedale Maggiore, Fondazione IRCCS Ca' Granda | Milan, Italy | Not Yet Recruiting |
| Ospedale Santa Maria della Misericordia dell'ASU-FC | Udine, Italy | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05925790